30
Participants
Start Date
February 28, 2009
Primary Completion Date
January 31, 2013
Study Completion Date
March 31, 2014
lenalidomide
"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
University of Pennsylvania Hospital Center, Philadelphia
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Medical College of Wisconsin, Milwaukee
University of Minnesota Medical Center, Minneapolis
The University of Texas, M.D. Anderson Cancer Center, Houston
City of Hope National Medical Center, Duarte
Fred Hutchinson Cancer Research Center, Seattle
Hackensack University Medical Center, Hackensack
Collaborators (1)
National Marrow Donor Program
OTHER
Celgene Corporation
INDUSTRY
Center for International Blood and Marrow Transplant Research
NETWORK